Cullinan Therapeutics (CGEM) Total Current Liabilities (2020 - 2026)

Cullinan Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $35.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 28.54% year-over-year to $35.2 million; the TTM figure through Mar 2026 stood at $35.2 million (up 28.54% YoY), while the FY2025 annual figure was $37.7 million, up 23.15% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $35.2 million, down from $37.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $62.0 million in Q2 2022, with the low at $17.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $27.1 million (2022), against an average of $28.7 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 980.18% in 2022, then plunged 68.28% in 2023.
• Cullinan Therapeutics' Total Current Liabilities stood at $22.5 million in 2022, then climbed by 25.06% to $28.1 million in 2023, then climbed by 8.92% to $30.6 million in 2024, then gained by 23.15% to $37.7 million in 2025, then declined by 6.85% to $35.2 million in 2026.
• Business Quant data shows CGEM's Total Current Liabilities at $35.2 million in Q1 2026, $37.7 million in Q4 2025, and $32.8 million in Q3 2025.